Interações de Dexametasona

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (bula de Abiraterona, Advertências e precauções)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (bula de Acalabrutinibe, Interações medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Adalimumabe, Advertência em caixa preta)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (bula de Alpelisibe, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (bula de Apixabana, Interações medicamentosas)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (bula de Apremilaste, Advertências e precauções)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (bula de Arformoterol, Contraindicações)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (bula de Aripiprazol, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (bula de Axitinibe, Advertências e precauções)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Baricitinibe, Advertência em caixa preta)

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Contraindicações)

Strong CYP3A4 Inducers: Avoid concomitant use. (bula de Bortezomibe, Interações medicamentosas)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (bula de Bosutinibe, Interações medicamentosas)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (bula de Buprenorfina, Interações medicamentosas)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Advertência em caixa preta)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (bula de Butalbital + paracetamol + cafeína + codeína, Advertência em caixa preta)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (bula de Cabozantinibe, Interações medicamentosas)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (bula de Cariprazina, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (bula de Clozapina, Interações medicamentosas)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (bula de Codeína, Advertência em caixa preta)

Avoid coadministration of cholestyramine and HEMADY and consider alternative agents. (bula de Dexametasona, Interações medicamentosas)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (bula de Daridorexanto, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (bula de Deflazacorte, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. (bula de Docetaxel, Advertência em caixa preta)

PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see Warnings and Precautions (5.2) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ] . (bula de Doravirina, Contraindicações)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (bula de Doxorrubicina, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (bula de Entricitabina + rilpivirina + tenofovir, Contraindicações)

…Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (bula de Epinefrina (adrenalina), Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Etanercepte, Advertência em caixa preta)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (bula de Fentanila, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (bula de Formoterol, Contraindicações)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (bula de Hidrocodona, Advertência em caixa preta)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (bula de Hidrocodona + clorfeniramina, Advertência em caixa preta)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (bula de Hidrocodona + homatropina, Advertência em caixa preta)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (bula de Hidrocodona + ibuprofeno, Advertência em caixa preta)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (bula de Hidrocodona + paracetamol, Advertência em caixa preta)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Infliximabe, Advertência em caixa preta)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (bula de Irinotecano, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (bula de Ivabradina, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Avoid strong CYP3A4 inducers. (bula de Lapatinibe, Interações medicamentosas)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (bula de Larotrectinibe, Interações medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (bula de Lemborexanto, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Venous and Arterial Thromboembolism REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with REVLIMID and dexamethasone therapy. (bula de Lenalidomida, Advertência em caixa preta)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (bula de Dexametasona, Advertências e precauções)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (bula de Dexametasona, Advertências e precauções)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (bula de Dexametasona, Advertências e precauções)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (bula de Lorlatinibe, Interações medicamentosas)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (bula de Lovastatina, Contraindicações)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (bula de Lumateperona, Interações medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (bula de Lurasidona, Contraindicações)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (bula de Mitotano, Advertência em caixa preta)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (bula de Moexipril, Advertências)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (bula de Naldemedina, Interações medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (bula de Naloxegol, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (bula de Nifedipino, Interações medicamentosas)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (bula de Nilotinibe, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (bula de Noretisterona + etinilestradiol, Interações medicamentosas)

If a CYP3A4 inducer is discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. (bula de Oliceridina, Interações medicamentosas)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (bula de Oxicodona, Advertência em caixa preta)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (bula de Oxicodona + paracetamol, Advertência em caixa preta)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (bula de Paliperidona, Interações medicamentosas)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (bula de Paracetamol + codeína, Advertência em caixa preta)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (bula de Pazopanibe, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in meperidine plasma concentration. (bula de Petidina (meperidina), Advertência em caixa preta)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (bula de Pimavanserina, Interações medicamentosas)

Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (bula de Pomalidomida, Advertências e precauções)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (bula de Praziquantel, Contraindicações)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (bula de Prometazina + codeína, Advertência em caixa preta)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (bula de Dexametasona, Advertências e precauções)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (bula de Rilpivirina, Contraindicações)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (bula de Rimegepanto, Interações medicamentosas)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (bula de Ritlecitinibe, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (bula de Rivaroxabana, Advertências e precauções)

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (bula de Rolapitanto, Interações medicamentosas)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (bula de Romidepsina, Interações medicamentosas)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (bula de Salmeterol, Advertência em caixa preta)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (bula de Sirolimo, Advertências e precauções)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (bula de Somatropina, Interações medicamentosas)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (bula de Tamoxifeno, Interações medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (bula de Tasimelteona, Interações medicamentosas)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (bula de Dexametasona, Advertências e precauções)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (bula de Dexametasona, Advertências e precauções)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (bula de Tiotepa, Interações medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Tocilizumabe, Advertência em caixa preta)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Tofacitinibe, Advertência em caixa preta)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (bula de Tolvaptana, Interações medicamentosas)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (bula de Toremifeno, Interações medicamentosas)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (bula de Trabectedina, Interações medicamentosas)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (bula de Tramadol, Advertência em caixa preta)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (bula de Tramadol + paracetamol, Advertência em caixa preta)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (bula de Trandolapril, Advertências)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (bula de Tretinoína, Advertência em caixa preta)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (bula de Trióxido de arsênio, Advertência em caixa preta)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (bula de Ubrogepanto, Interações medicamentosas)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Ulipristal, Advertências e precauções)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (bula de Umeclidínio + vilanterol, Contraindicações)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (bula de Upadacitinibe, Advertência em caixa preta)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (bula de Valbenazina, Interações medicamentosas)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (bula de Vepdegestranto, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (bula de Dexametasona, Interações medicamentosas)

John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. (bula de Zolpidem, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Monitor for toxicity when aspirin is used in conjunction with HEMADY in hypoprothrombinemia. (bula de Dexametasona, Interações medicamentosas)

Monitor for toxicity when aspirin is used in conjunction with HEMADY in hypoprothrombinemia. (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Ácido valproico, Interações medicamentosas)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (bula de Ácido zoledrônico, Advertências e precauções)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (bula de Aclidínio, Interações medicamentosas)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (bula de Afatinibe, Advertências e precauções)

Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when dexamethasone was coadministered with each dose of albendazole. (bula de Albendazol, Interações medicamentosas)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (bula de Alendronato, Advertências e precauções)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (bula de Alentuzumabe, Advertências e precauções)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (bula de Alisquireno, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

• Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (bula de Alprazolam, Interações medicamentosas)

Amphotericin B Injection and Potassium-Depleting Agents Sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids [see Warnings and Precautions ( ‎5.3 ), and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Anlodipino, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Anlodipino + atorvastatina, Interações medicamentosas)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (bula de Anlodipino + benazepril, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Anlodipino + olmesartana, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (bula de Anlodipino + valsartana, Interações medicamentosas)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (bula de Dexametasona, Interações medicamentosas)

Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (bula de Beclometasona, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Beladona + ópio, Advertências e precauções)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (bula de Bendamustina, Advertências e precauções)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (bula de Benralizumabe, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (bula de Brexpiprazol, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Budesonida + formoterol, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Buprenorfina + naloxona, Advertências e precauções)

…risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (bula de Bupropiona, Advertências e precauções)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (bula de Buspirona, Interações medicamentosas)

Monitor for toxicity when aspirin is used in conjunction with HEMADY in hypoprothrombinemia. (bula de Dexametasona, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Butorfanol, Advertências)

• Strong inducer of CYP3A4 or CYP2C19: Consider dose increase of EPIDIOLEX. (bula de Canabidiol (medicamento de prescrição), Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

…Enzymes Adults : When Caspofungin acetate for Injection is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of Caspofungin acetate for Injection should be considered [see Dosage and Administration ( 2.5 ) and Clinical… (bula de Caspofungina, Interações medicamentosas)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (bula de Cefoxitina, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Ciprofloxacino, Advertências e precauções)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (bula de Citarabina, Advertências)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (bula de Clindamicina, Interações medicamentosas)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (bula de Clomipramina, Interações medicamentosas)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (bula de Cocaína, Interações medicamentosas)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (bula de Daptomicina, Advertências e precauções)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (bula de Deferasirox, Advertências e precauções)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (bula de Denosumabe, Advertências e precauções)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

Clinically Relevant Interactions Affecting DEXILANT When Coadministered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (bula de Dexlansoprazol, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (bula de Dicicloverina, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia [ see Warnings and Precautions (‎ 5.3 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (bula de Dofetilida, Interações medicamentosas)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (bula de Doxercalciferol, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (bula de Dupilumabe, Advertências e precauções)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

Ephedrine Ephedrine may decrease dexamethasone exposure. (bula de Dexametasona, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (bula de Erlotinibe, Advertências e precauções)

Table 4: Clinically Relevant Interactions Affecting Esomeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (bula de Esomeprazol, Interações medicamentosas)

While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations. (bula de Estazolam, Advertências)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (bula de Eszopiclona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

Systemic dexamethasone should be used with caution or alternatives should be considered, particularly for long-term use. (bula de Etravirina, Interações medicamentosas)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (bula de Exemestano, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (bula de Fenilacetato de sódio + benzoato de sódio, Interações medicamentosas)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (bula de Fenilbutirato de glicerol, Interações medicamentosas)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (bula de Fenilbutirato de sódio, Interações medicamentosas)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (bula de Fenilefrina, Interações medicamentosas)

Phenytoin In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone coadministration, leading to alterations in seizure control. (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (bula de Fesoterodina, Interações medicamentosas)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (bula de Fingolimode, Advertências e precauções)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (bula de Flecainida, Interações medicamentosas)

Pregnancy As with other corticosteroids, flunisolide has been shown to be teratogenic and fetotoxic in rabbits and rats at oral doses of 40 and 200 mcg/kg/day, respectively (approximately 2 and 4 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m 2 basis). (bula de Flunisolida, Precauções)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (bula de Fluocinonida, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (bula de Fluticasona + salmeterol, Advertências e precauções)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels… (bula de Fosfenitoína, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (bula de Guanfacina, Interações medicamentosas)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (bula de Halobetasol, Advertências e precauções)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (bula de Haloperidol, Interações medicamentosas)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (bula de Hidralazina, Advertências)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (bula de Hidrocortisona, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Hidromorfona, Advertências e precauções)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (bula de Ibandronato, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (bula de Ifosfamida, Interações medicamentosas)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (bula de Imipramina, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (bula de Ivermectina, Advertências)

Clinically Relevant Interactions Affecting PREVACID or PREVACID SoluTab When Coadministered with Other Drugs CYP2C19 OR CYP3A4 Inducers Clinical Impact: Decreased exposure of lansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (bula de Lansoprazol, Interações medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Levofloxacino, Advertências e precauções)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids and increase exposures, which may increase the risk of adverse reactions [see Warnings and Precautions ( ‎5 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Levorfanol, Advertências)

If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (bula de Levossalbutamol, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (bula de Lisinopril + hidroclorotiazida, Advertências)

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily. (bula de Maraviroque, Advertências e precauções)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (bula de Margetuximabe, Advertências e precauções)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids and increase exposures, which may increase the risk of adverse reactions [see Warnings and Precautions ( ‎5 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Rifampin (Potent Inducer of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine and 600 mg of rifampin once daily for 7 days in 7 healthy Thai volunteers resulted in a decrease in the mean C max and AUC of mefloquine by 19% and 68%, respectively, and a decrease in the mean elimination half-life of mefloquine from 305 hours to 113 hours. (bula de Mefloquina, Interações medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids and increase exposures, which may increase the risk of adverse reactions [see Warnings and Precautions ( ‎5 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (bula de Dexametasona, Interações medicamentosas)

Decrease corticosteroids gradually, if appropriate. (bula de Mepolizumabe, Advertências e precauções)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (bula de Dexametasona, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Metadona, Advertências e precauções)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (bula de Metazolamida, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

If not, corticosteroids may be given and other causes of anemia should be considered. (bula de Metildopa, Advertências)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (bula de Metilprednisolona, Interações medicamentosas)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (bula de Metiltestosterona, Advertências)

This can be corrected by giving appropriate doses of corticosteroids. (bula de Metirapona, Advertências e precauções)

Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (bula de Metolazona, Interações medicamentosas)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (bula de Metotrexato, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (bula de Mirtazapina, Interações medicamentosas)

Lung function (FEV 1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (bula de Mometasona, Advertências e precauções)

Inhaled corticosteroid may be reduced gradually. (bula de Montelucaste, Advertências e precauções)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Morfina, Advertências e precauções)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Moxifloxacino, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Nalbufina, Advertências)

…hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (bula de Naltrexona + bupropiona, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (bula de Natalizumabe, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (bula de Nimodipino, Advertências e precauções)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (bula de Nintedanibe, Advertências e precauções)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids and increase exposures, which may increase the risk of adverse reactions [see Warnings and Precautions ( ‎5 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

(‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (bula de Dexametasona, Interações medicamentosas)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (bula de Ocrelizumabe, Advertências e precauções)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (bula de Ofloxacino, Advertências)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (bula de Omalizumabe, Advertências e precauções)

Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (bula de Omeprazol, Interações medicamentosas)

Table 6: Clinically Relevant Interactions Affecting Omeprazole when Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (bula de Omeprazol + bicarbonato de sódio, Interações medicamentosas)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

Monitor for toxicity when aspirin is used in conjunction with HEMADY in hypoprothrombinemia. (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Oximorfona, Advertências e precauções)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (bula de Pamidronato, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (bula de Penicilamina, Advertências)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Pentazocina + naloxona, Advertências)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (bula de Ponesimode, Advertências e precauções)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (bula de Prednisolona, Interações medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (bula de Prednisona, Interações medicamentosas)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids and increase exposures, which may increase the risk of adverse reactions [see Warnings and Precautions ( ‎5 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (bula de Propofol, Advertências e precauções)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (bula de Quetiapina, Interações medicamentosas)

Antiepileptics (AEDs) (Carbamazepine, Phenobarbital, and Phenytoin) Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate. (bula de Quinina, Interações medicamentosas)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (bula de Ramelteona, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. (bula de Rifabutina, Interações medicamentosas)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (bula de Rifampicina, Interações medicamentosas)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (bula de Rifapentina, Interações medicamentosas)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (bula de Risedronato, Advertências e precauções)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (bula de Risperidona, Interações medicamentosas)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (bula de Rocurônio, Advertências e precauções)

Effects of Other AEDs on BANZEL Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital, appear to increase the clearance of BANZEL (see Table 6). (bula de Rufinamida, Interações medicamentosas)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (bula de Ruxolitinibe, Interações medicamentosas)

If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (bula de Salbutamol, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (bula de Selegilina, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (bula de Dexametasona, Interações medicamentosas)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (bula de Suxametônio (succinilcolina), Interações medicamentosas)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (bula de Tacrolimo, Advertências e precauções)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (bula de Tadalafila, Interações medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (bula de Tapentadol, Advertências e precauções)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (bula de Telmisartana + anlodipino, Interações medicamentosas)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (bula de Temozolomida, Advertências e precauções)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (bula de Tensirolimo, Advertências e precauções)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (bula de Teofilina, Advertências)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (bula de Terbinafina, Interações medicamentosas)

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (bula de Terbutalina, Advertências)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (bula de Tesamorrelina, Interações medicamentosas)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (bula de Testosterona, Advertências e precauções)

Use of tiagabine HCl without enzyme-inducing antiepileptic drugs results in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION ). (bula de Tiagabina, Advertências)

CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions ( 7.2 ) (bula de Tinidazol, Interações medicamentosas)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (bula de Tiotixeno, Interações medicamentosas)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (bula de Tiotrópio, Interações medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (bula de Dexametasona, Advertências e precauções)

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects [see Warnings and Precautions (‎ 5.7 ) and Adverse Reactions (‎ 6 )] . (bula de Dexametasona, Interações medicamentosas)

Corticosteroids and ACTH: Increased risk of hypokalemia. (bula de Torasemida, Interações medicamentosas)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (bula de Trastuzumabe, Advertências e precauções)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (bula de Trazodona, Interações medicamentosas)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (bula de Treprostinila, Advertências e precauções)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (bula de Triancinolona, Interações medicamentosas)

Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (bula de Triantereno + hidroclorotiazida, Interações medicamentosas)

Strong Inducers of CYP 3A Clinical implication Coadministration of triazolam with strong inducers of CYP3A4 can significantly decrease the plasma concentration of triazolam and may decrease effectiveness of triazolam. (bula de Triazolam, Interações medicamentosas)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (bula de Dexametasona, Advertências e precauções)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (bula de Vilazodona, Interações medicamentosas)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (bula de Zaleplona, Interações medicamentosas)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (bula de Zenocutuzumabe, Advertências e precauções)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (bula de Ziprasidona, Interações medicamentosas)

CYP3A4 Inducers If co-administration with a potent CYP3A4 inducer is necessary, the patient should be closely monitored and the dose of ZONISAMIDE and other drugs that CYP3A4 substrates may need to be adjusted [see Clinical Pharmacology ( 12.3 )] . (bula de Zonisamida, Interações medicamentosas)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (bula de Ácido bempedoico, Advertências e precauções)

Care should also be exercised in patients receiving potassium-depleting steroids. (bula de Ácido etacrínico, Advertências)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (bula de Alteplase, Advertências e precauções)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (bula de Amicacina, Advertências e precauções)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (bula de Ampicilina, Advertências)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (bula de Anfetamina, Interações medicamentosas)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (bula de Anfetamina + dextroanfetamina, Interações medicamentosas)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (bula de Benzilpenicilina (penicilina G), Advertências)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (bula de Bevacizumabe, Advertências e precauções)

Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (bula de Bisoprolol + hidroclorotiazida, Precauções)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (bula de Bussulfano, Advertências)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (bula de Calcitriol, Interações medicamentosas)

Steroids or Adrenocorticotropic Hormone – Hypokalemia may develop during concomitant use of steroids or adrenocorticotropic hormone (ACTH). (bula de Candesartana + hidroclorotiazida, Interações medicamentosas)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (bula de Carbamazepina, Interações medicamentosas)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefaclor, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefadroxila, Advertências e precauções)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefdinir, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefotetana, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Cefprozila, Advertências)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (bula de Ceftazidima, Advertências)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (bula de Ceftriaxona, Advertências e precauções)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (bula de Clofarabina, Advertências e precauções)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (bula de Clomifeno, Advertências)

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate (CYP2C19 inhibitor and CYP3A4 inducer) do not affect the pharmacokinetics of clonazepam. (bula de Clonazepam, Interações medicamentosas)

Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. (bula de Clorotiazida, Interações medicamentosas)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (bula de Corticotropina, Advertências e precauções)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (bula de Dextroanfetamina, Interações medicamentosas)

Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. (bula de Disopiramida, Interações medicamentosas)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Dexametasona, Interações medicamentosas)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (bula de Droperidol, Interações medicamentosas)

Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. (bula de Enalapril + hidroclorotiazida, Interações medicamentosas)

TAF is not an inhibitor or inducer of CYP3A in vivo . (bula de Entricitabina + tenofovir, Interações medicamentosas)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (bula de Eribulina, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur. (bula de Espironolactona + hidroclorotiazida, Interações medicamentosas)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (bula de Fenoximetilpenicilina (penicilina V), Advertências)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Dexametasona, Interações medicamentosas)

Steroids may or may not be effective in controlling these hemolytic episodes. (bula de Fludarabina, Advertências e precauções)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (bula de Fluoxetina, Advertências e precauções)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Dexametasona, Interações medicamentosas)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (bula de Glucagon, Advertências e precauções)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (bula de Guselcumabe, Advertências e precauções)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (bula de Ipratrópio, Interações medicamentosas)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (bula de Melfalana, Advertências)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (bula de Metanfetamina, Interações medicamentosas)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (bula de Metoexital, Advertências)

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexiletine, lowered mexiletine plasma levels have been reported. (bula de Mexiletina, Interações medicamentosas)

Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (bula de Midodrina, Interações medicamentosas)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (bula de Mitoxantrona, Interações medicamentosas)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (bula de Naltrexona, Advertências e precauções)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Dexametasona, Interações medicamentosas)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (bula de Olanzapina + fluoxetina, Advertências e precauções)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + hidroclorotiazida, Interações medicamentosas)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (bula de Oxacilina, Advertências)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Dexametasona, Interações medicamentosas)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (bula de Raloxifeno, Interações medicamentosas)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (bula de Riociguate, Interações medicamentosas)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (bula de Rituximabe, Advertências e precauções)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Dexametasona, Interações medicamentosas)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (bula de Tenecteplase, Advertências e precauções)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (bula de Ustequinumabe, Advertências e precauções)

Concurrent use of strong CYP3A inducers (e.g., St. (bula de Vincristina, Interações medicamentosas)

Corticosteroides como a prednisona reduzem a absorção de cálcio e prejudicam o metabolismo da vitamina D, contribuindo para a perda óssea. (NIH Office of Dietary Supplements, Vitamin D)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (bula de Asenapina, Interações medicamentosas)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (bula de Micafungina, Interações medicamentosas)